InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (11 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
11
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Loose Christopher R., Directeur Scientifique. Officer active across 1 company, notably Frequency Therapeutics, Inc.. Cumulatively, 15 reports have been logged. Split: 0 buy · 11 sells. Total volume traded: €12k. Activity tracked since 16 February 2022. The latest transaction was disclosed on 27 July 2023 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Loose Christopher R.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
1,373 shares@ US$0.534.3% of flowCommon StockSEC:0001127602-23-021561:0
1,390 shares@ US$0.504.1% of flowCommon StockSEC:0000950170-23-035163:0
1,333 shares@ US$0.614.7% of flowCommon StockSEC:0000950170-23-034475:0
1,335 shares@ US$0.655.0% of flowCommon StockSEC:0001127602-23-021133:0
1,415 shares@ US$0.675.5% of flowCommon StockSEC:0001127602-23-020997:0
1,329 shares@ US$0.393.0% of flowCommon StockSEC:0001127602-23-020819:0
1,363 shares@ US$0.373.0% of flowCommon StockSEC:0001127602-23-020671:0
1,306 shares@ US$0.362.8% of flowCommon StockSEC:0000950170-23-032734:0
150,000 sharesCommon StockSEC:0000950170-23-032730:0
1,306 shares@ US$0.362.8% of flowCommon StockSEC:0001127602-23-020573:0
4,546 sharesCommon StockSEC:0001127602-23-020471:0
15,000 sharesCommon StockSEC:0001127602-22-019051:0
974 shares@ US$3.87333.3% of flowCommon StockSEC:0001127602-22-006339:0
851 shares@ US$4.42933.3% of flowCommon StockSEC:0001127602-22-005752:0
15,000 sharesCommon StockSEC:0001127602-22-005331:0
15 of 15 declarations
About Loose Christopher R.
Christopher R. Loose is the Chief Scientific Officer of Frequency Therapeutics, Inc. In this role, he is responsible for scientific leadership and innovation within the company. Christopher plays a key role in developing new therapies and technologies, thereby contributing to advancements in science and health. His expertise is essential in positioning Frequency Therapeutics as a leader in the biotechnology field.
